Information Provided By: 
Fly News Breaks for February 21, 2019
IART
Feb 21, 2019 | 15:10 EDT
Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $62 price target on Integra LifeSciences after the company reported better-than-expected Q4 earnings, including Q4 sales of $383.3M which represented growth of ~4% and was on the higher end of the company's preannounced range of $378-383M. Additionally, Integra guided for FY19 adjusted earnings of $2.64-$2.72, ahead of Piper's previous estimate of $2.61.
News For IART From the Last 2 Days
There are no results for your query IART
